Clinical characteristics of subjects at baseline and at follow-up
| . | Negative group . | Constitutional thrombophilia group . | aPLAb group . | P . |
|---|---|---|---|---|
| n | 796 | 279 | 517 | |
| Age, y | 30 (5) [17-44] | 29 (4) [18-44] | 29 (4) [16-41] | .21 |
| Age > 35 y | 43 (5.4%) | 12 (4.3%) | 15 (2.9%) | .086 |
| Body mass index, kg/m2 | 25.6 (4.5) [15.3-36.1] | 25.9 (4.2) [13.5-34.1] | 26.0 (4.6) [15.3-37.0] | .16 |
| > 30 | 78 (9.8%) | 29 (10.4%) | 60 (11.6%) | .58 |
| < 18.5 | 12 (1.5%) | 3 (1.1%) | 5 (1%) | .66 |
| Ethnicity | .87 | |||
| White | 753 (94.6%) | 264 (94.6%) | 489 (94.6%) | |
| European | 647 (81.3%) | 227 (81.4%) | 420 (81.2%) | |
| North African | 106 (13.3%) | 37 (13.2%) | 69 (13.4%) | |
| Black African | 36 (4.5%) | 12 (4.3%) | 22 (4.2%) | |
| Asian | 7 (0.9%) | 3 (1.1%) | 6 (1.2%) | |
| Pregnancy loss subtype | ||||
| Embryonic at < 10 WG | 483 (60.7%) | 93 (33.3%) | 206 (39.8%) | < .0001 |
| Fetal at ≥ 10 WG | 313 (39.3%) | 186 (66.6%) | 311 (60.2%) | |
| Primary | 549 (68.9%) | 185 (66.3%) | 342 (66.1%) | .49 |
| Secondary | 247 (31.1%) | 94 (33.7%) | 175 (33.9%) | |
| Inflammatory disease | 7 (0.9%) | 4 (1.4%) | 32 (6.2%) | < .0001 |
| Current smokers | 83 (10.4%) | 30 (10.8%) | 50 (9.7%) | .89 |
| Hypertension | 19 (2.4%) | 8 (2.9%) | 17 (3.3%) | .62 |
| Positive history in a first-degree relative | ||||
| Venous thromboembolism | 15 (1.9%) | 29 (10.4) | 12 (2.3%) | < .0001 |
| Atherothrombosis | 96 (12.1%) | 46 (16.5%) | 53 (10.3%) | .043 |
| Hyperlipidemia | ||||
| Hypercholesterolemia | 42 (5.3%) | 13 (4.7%) | 31 (6.0%) | .71 |
| Hypertriglyceridemia | 34 (4.3%) | 11 (3.9%) | 27 (5.2%) | .64 |
| Varicose veins | 187 (23.5%) | 58 (20.8%) | 117 (22.6%) | .65 |
| Hormonal contraception, n (%) | ||||
| Oral, estroprogestative | 38 (4.8%) | 2 (0.7%) | 5 (0.9%) | < .0001 |
| Oral, progestin only | 5 (0.6%) | 14 (5.0%) | 27 (5.2%) | < .0001 |
| Lipid-lowering drugs | 0 | 0 | 0 | |
| Follow-up duration, d | 3572 (1860) [254-5461] | 3457 (1781) [274-5452] | 3392 (1893) [206-5449] | .023 |
| . | Negative group . | Constitutional thrombophilia group . | aPLAb group . | P . |
|---|---|---|---|---|
| n | 796 | 279 | 517 | |
| Age, y | 30 (5) [17-44] | 29 (4) [18-44] | 29 (4) [16-41] | .21 |
| Age > 35 y | 43 (5.4%) | 12 (4.3%) | 15 (2.9%) | .086 |
| Body mass index, kg/m2 | 25.6 (4.5) [15.3-36.1] | 25.9 (4.2) [13.5-34.1] | 26.0 (4.6) [15.3-37.0] | .16 |
| > 30 | 78 (9.8%) | 29 (10.4%) | 60 (11.6%) | .58 |
| < 18.5 | 12 (1.5%) | 3 (1.1%) | 5 (1%) | .66 |
| Ethnicity | .87 | |||
| White | 753 (94.6%) | 264 (94.6%) | 489 (94.6%) | |
| European | 647 (81.3%) | 227 (81.4%) | 420 (81.2%) | |
| North African | 106 (13.3%) | 37 (13.2%) | 69 (13.4%) | |
| Black African | 36 (4.5%) | 12 (4.3%) | 22 (4.2%) | |
| Asian | 7 (0.9%) | 3 (1.1%) | 6 (1.2%) | |
| Pregnancy loss subtype | ||||
| Embryonic at < 10 WG | 483 (60.7%) | 93 (33.3%) | 206 (39.8%) | < .0001 |
| Fetal at ≥ 10 WG | 313 (39.3%) | 186 (66.6%) | 311 (60.2%) | |
| Primary | 549 (68.9%) | 185 (66.3%) | 342 (66.1%) | .49 |
| Secondary | 247 (31.1%) | 94 (33.7%) | 175 (33.9%) | |
| Inflammatory disease | 7 (0.9%) | 4 (1.4%) | 32 (6.2%) | < .0001 |
| Current smokers | 83 (10.4%) | 30 (10.8%) | 50 (9.7%) | .89 |
| Hypertension | 19 (2.4%) | 8 (2.9%) | 17 (3.3%) | .62 |
| Positive history in a first-degree relative | ||||
| Venous thromboembolism | 15 (1.9%) | 29 (10.4) | 12 (2.3%) | < .0001 |
| Atherothrombosis | 96 (12.1%) | 46 (16.5%) | 53 (10.3%) | .043 |
| Hyperlipidemia | ||||
| Hypercholesterolemia | 42 (5.3%) | 13 (4.7%) | 31 (6.0%) | .71 |
| Hypertriglyceridemia | 34 (4.3%) | 11 (3.9%) | 27 (5.2%) | .64 |
| Varicose veins | 187 (23.5%) | 58 (20.8%) | 117 (22.6%) | .65 |
| Hormonal contraception, n (%) | ||||
| Oral, estroprogestative | 38 (4.8%) | 2 (0.7%) | 5 (0.9%) | < .0001 |
| Oral, progestin only | 5 (0.6%) | 14 (5.0%) | 27 (5.2%) | < .0001 |
| Lipid-lowering drugs | 0 | 0 | 0 | |
| Follow-up duration, d | 3572 (1860) [254-5461] | 3457 (1781) [274-5452] | 3392 (1893) [206-5449] | .023 |
Quantitative data are given as median (interquartile range) [range] and qualitative data as number (percentage) values.
WG indicates weeks of gestation.